Prescriptions for off-label medications; terms; moral, ethical, or religious exemptions; immunity from liability; good- faith effort; temporary privileges; at-home and outpatient dispensing; disciplinary action; exceptions; World Health Organization; effective date.
HB1344 creates a new section of Oklahoma law governing the prescribing and dispensing of off-label drugs. It defines key terms such as off-label drug, informed consent, prescriber, pharmacist, hospital, and inpatient facility, and authorizes prescribers to issue prescriptions for off-label uses so long as informed consent is obtained from the patient, parent or guardian, or health care power of attorney. The bill also removes any requirement that a patient first have a positive test, screen, or known exposure to a disease, illness, or infection before an off-label prescription may be written or dispensed, including for prophylactic use, so long as the drug is not a controlled dangerous substance and any FDA Risk Evaluation and Mitigation Strategy requirements are followed.
The bill requires pharmacists, hospitals, and inpatient facilities to dispense or allow dispensing of qualifying off-label prescriptions unless they have a moral, ethical, or religious objection, or there is a documented life-threatening allergy or contraindication. It also creates immunity from administrative and civil liability for certain good-faith, scientifically based objections that are documented in the patient record, and it allows a pharmacist or facility to discuss a prescription with the prescriber without limiting the patient’s ultimate informed choice. In hospital settings, the bill sets procedures for obtaining off-label drugs, including efforts to locate drugs from other facilities or distributors, permission to bring in drugs from outside the facility, and a process for temporary privileges for an outpatient prescriber to participate in care when the patient cannot safely be transported.
HB1344 would also limit disciplinary action by health-related licensing boards and other state agencies, barring them from treating actions taken under the section as unlawful, unethical, unauthorized, or unprofessional conduct except in cases of recklessness or gross negligence. In addition, it prohibits boards and agencies from disciplining licensed professionals for publicly or privately expressing medical opinions that differ from those of the agency. The bill further states that the World Health Organization has no jurisdiction in Oklahoma and bars state and local entities from enforcing or funding WHO guidance that would prohibit off-label prescribing or dispensing.
The bill’s impact on state law would be significant for prescribing authority, pharmacy practice, hospital operations, and professional discipline. It would add a new statutory framework in Title 59 that expands access to off-label medications, creates explicit rights and exemptions for providers and facilities, and imposes new procedural obligations on hospitals and the Department of Health, including complaint recordkeeping related to denied temporary privileges. It also appears to preempt contrary guidance from state agencies and political subdivisions regarding off-label drug use.
No committee transcript or vote record was provided, so there is no documented floor or committee sentiment to assess. Based on the bill text alone, the measure appears designed to strongly protect prescriber and pharmacist discretion and to reduce regulatory or disciplinary barriers, while also creating broad conscience-based exemptions. Likely points of contention include the scope of off-label prescribing authority, the mandatory dispensing provisions, the immunity and anti-discipline protections, the temporary privileges process in hospitals, and the bill’s unusual declaration limiting World Health Organization influence in the state.
The bill would add Section 355.7 to Title 59 of the Oklahoma Statutes and would regulate off-label prescribing and dispensing by prescribers, pharmacists, hospitals, and inpatient facilities. It would expand legal protection for off-label drug use, require informed consent, create conscience-based exemptions, limit professional discipline, and establish procedures for temporary hospital privileges and complaint retention by the Department of Health. It would also bar state and local entities from enforcing WHO guidance that conflicts with off-label prescribing or dispensing.
No committee discussion or vote history was provided, so there is no recorded legislative sentiment to summarize. From the bill text, the measure appears to be framed as a pro-prescriber, pro-access bill that also protects moral, ethical, and religious objections. Its structure suggests support for expanded treatment discretion, but it also contains provisions likely to draw concern from regulators, hospitals, and some health professionals because it limits agency oversight and mandates certain dispensing practices.
The main points of contention are likely to be the bill’s broad authorization of off-label prescribing without requiring a positive test or known exposure, the requirement that pharmacists and facilities dispense qualifying prescriptions absent narrow exceptions, and the immunity from discipline except for recklessness or gross negligence. Hospitals may object to the temporary privileges process and the requirement to allow outside drugs into the facility, while licensing boards may object to the restrictions on their disciplinary authority. The World Health Organization jurisdiction clause is also likely to be controversial because it goes beyond ordinary pharmacy regulation and appears aimed at rejecting external public health guidance.